Quantitative assessment of residual tumor is a strong and independent predictor of survival in methylated glioblastoma following radiochemotherapy with CCNU/TMZ.
Neuro-oncology
View this publicationNeuro-oncology
View this publicationJournal of cancer research and clinical oncology
View this publicationAnnals of clinical and translational neurology
View this publicationAnnals of neurology
View this publicationJournal of neurology
View this publicationInvestigative radiology
View this publicationDiagnostics (Basel, Switzerland)
View this publicationNeuroradiology
View this publicationInvestigative radiology
View this publicationScientific reports
View this publication